Health Care Equipment

Aspira Women Health

Aspira Women's Health Inc. signs five-year laboratory services agreement with Mayo Clinic Laboratories

Aspira Women's Health Inc. Announces Q1 2025 Financials and Future R&D Plans

Aspira Women’s Health Files Initial Beneficial Ownership Statement with SEC

Aspira Women’s Health Inc Signs Stock Purchase Agreement with Triton Funds

Aspira Women Health released FY2024 Q4 earnings on March 27 (EST), actual revenue 2.349 M USD (forecast 3 M USD), actual EPS -0.083 USD (forecast -0.4 USD)

Aspira Women Health released FY2024 annual earnings on March 27 (EST), actual revenue 9.182 M USD (forecast 11 M USD), actual EPS -0.9263 USD (forecast -1.55 USD)

Aspira Women’s Health Submits Application for Up to 50 Units, 50 Million Pre-Financing Units

Aspira Women Health released FY2024 Q3 earnings on November 19 Pre-Market (EST), actual revenue 2.257 M USD (forecast 2.734 M USD), actual EPS -0.2302 USD (forecast -0.245 USD)

Aspira Women Health released FY2024 Cumulative 3Q Earnings on November 19, 2024 (EST) with Revenue of 6.833 M USD and EPS of -0.9029

Aspira Women Health to Release FY2024 9 Months Earnings on November 14, Pre-Market EST; Forecast Revenue 2.734 M USD, EPS -0.245 USD

Aspira Women's Health Inc. Announces Partnership with Investor Catalyst Center

EKSO Bionics

BUUU

Antelope Enterprise

CID Holdco

Profusa

Aimei Health Tech

Urgently

ON24

Jyong Biotech

Zhongchao

Delcath

Electromed

Abbott Laboratories

Intuitive Surgical

Boston Scientific

Stryker

IDEXX Labs

Edwards Lifesciences

Resmed

DexCom

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap